Track topics on Twitter Track topics that are important to you
SAINT-LAURENT, QUEBEC -- (Marketwired) -- 08/30/17 -- IntelGenx Technologies Corp., (TSX VENTURE: IGX)(OTCQX: IGXT), today announced that its President and Chief Executive Officer, Dr. Horst Zerbe, is scheduled to present at the Rodman & Renshaw 19th Annual Global Investment Conference on Monday, September 11 at 12:30 p.m. Eastern Time at the at the Lotte New York Palace Hotel.
Dr. Zerbe will provide an overview of IntelGenx' business during the presentation and, along with Andre Godin, Executive Vice-President and Chief Financial Officer, will be available to participate in one-on-one meetings with investors who are registered to attend the conference.
The presentation will be webcast live and archived for 90 days on the Company's website, www.intelgenx.com, under "Investors".
Established in 2003, IntelGenx is a leading oral drug delivery company primarily focused on the development and manufacturing of innovative pharmaceutical oral films based on its proprietary VersaFilm technology platform.
IntelGenx' highly skilled team provides comprehensive pharmaceuticals services to pharmaceutical partners, including R&D, analytical method development, clinical monitoring, IP and regulatory services. IntelGenx' state-of-the-art manufacturing facility, established for the VersaFilm technology platform, supports lab-scale to pilot and commercial-scale production, offering full service capabilities to its clients. More information about the company can be found at www.intelgenx.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange), nor the OTCQX accepts responsibility for the adequacy or accuracy of this release.
Source: IntelGenx Technologies Corp.Contacts: Stephen Kilmer Investor Relations (514) 331-7440 ext 232 Andre Godin, CPA, CA Executive Vice-President and CFO (514) 331-7440 ext 203 NEXT ARTICLE
<!--LGfEGNT2Lhm-->Drug delivery is the method or process of administering a pharmaceutical compound to achieve a therapeutic effect in humans or animals. <!--LGfEGNT2Lhm-->Drug delivery technologies are <!--LGfEGNT2Lhm-->patent pr...
Standard antiretroviral therapy (ART) consists of the combination of at least three antiretroviral (ARV) drugs to maximally suppress the HIV virus and stop the progression of HIV disease. Huge reductions have been seen in rates of death and suffering whe...